Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investors concerning whether the company’s officers and board of directors violated the federal securities laws.

On January 15, 2016, the U.S. Food and Drug Administration published a report concerning Sarepta’s pending drug application stating that “we cannot approve drugs for which substantial evidence of effectiveness has not been established.”

If you purchased Sarepta securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.